Plant-Based Vaccines

Aboul-Ata, Aboul-Ata E.; Vitti, Antonella; Nuzzaci, Maria; El-Attar, Ahmed K.; Piazzolla, Giuseppina; Tortorella, Cosimo; Harandi, Ali M.; Olson, O. Paul; Wright, Sandra A. I.; Piazzolla, P.

doi:10.1016/b978-0-12-800172-1.00001-x

Cited by 25 publications

(8 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plants can be grown in a greenhouse or even in a biosafety lab if required. The cost of plant maintenance for PMF is low, relative to E. coli , yeast, or mammalian cell expression systems (see Table 3 ); and the source (plant leaves or seeds) for making the recombinant protein is potentially unlimited [ 7 , 8 , 35 ]. Plant expression systems have several major advantages over prokaryotic and other eukaryotic cell systems in regards to production speed, cost, and safety.…”

Section: Advantagesmentioning

confidence: 99%

“…An example of an early proof of concept for PMF is the production of plant-derived edible human vaccines, using leafy plants or fruits [ 30 , 31 , 32 , 33 , 34 , 35 ]. Edible vaccines are an ideal product in concept since the vaccine could be administered to people orally, theoretically without the need of professional health care workers or sterile injections.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plants as Factories for Human Pharmaceuticals: Applications and Challenges

Yao

Weng

Dickey

et al. 2015

IJMS

219

162

View full text Add to dashboard Cite

Plant molecular farming (PMF), defined as the practice of using plants to produce human therapeutic proteins, has received worldwide interest. PMF has grown and advanced considerably over the past two decades. A number of therapeutic proteins have been produced in plants, some of which have been through pre-clinical or clinical trials and are close to commercialization. Plants have the potential to mass-produce pharmaceutical products with less cost than traditional methods. Tobacco-derived antibodies have been tested and used to combat the Ebola outbreak in Africa. Genetically engineered immunoadhesin (DPP4-Fc) produced in green plants has been shown to be able to bind to MERS-CoV (Middle East Respiratory Syndrome), preventing the virus from infecting lung cells. Biosafety concerns (such as pollen contamination and immunogenicity of plant-specific glycans) and costly downstream extraction and purification requirements, however, have hampered PMF production from moving from the laboratory to industrial application. In this review, the challenges and opportunities of PMF are discussed. Topics addressed include; transformation and expression systems, plant bioreactors, safety concerns, and various opportunities to produce topical applications and health supplements.

show abstract

Section: Advantagesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plants as Factories for Human Pharmaceuticals: Applications and Challenges

Yao

Weng

Dickey

et al. 2015

IJMS

219

162

View full text Add to dashboard Cite

show abstract

“…Plant-made vaccines lack the safety considerations that are associated with conventional vaccines and cannot be subject to contamination by human pathogens, are easy to upscale, cheap, and lack refrigeration requirements as well as a sophisticated medical infrastructure [ 4 , 5 ]. These attributes have provided plant-made pharmaceuticals with an opportunity to assist those in resource poor settings to receive medicines that were previously inaccessible [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Repurposing Plant Virus Nanoparticles

Hefferon

2018

Vaccines

View full text Add to dashboard Cite

Plants have been explored for many years as inexpensive and versatile platforms for the generation of vaccines and other biopharmaceuticals. Plant viruses have also been engineered to either express subunit vaccines or act as epitope presentation systems. Both icosahedral and helical, filamentous-shaped plant viruses have been used for these purposes. More recently, plant viruses have been utilized as nanoparticles to transport drugs and active molecules into cancer cells. The following review describes the use of both icosahedral and helical plant viruses in a variety of new functions against cancer. The review illustrates the breadth of variation among different plant virus nanoparticles and how this impacts the immune response.

show abstract

“…The HRV1 epitope found on the envelope protein of HCV has also been expressed in tobacco plants using recombinant vectors based on Alfalfa mosaic virus and TMV [ 28 ]. Uhde-Holzem et al .…”

Section: Plant-derived Vaccine Against Hepatitis C Virusmentioning

confidence: 99%

Reconceptualizing Cancer Immunotherapy Based on Plant Production Systems

Hefferon

2017

Future Sci. OA

View full text Add to dashboard Cite

Plants can be used as inexpensive and facile production platforms for vaccines and other biopharmaceuticals. More recently, plant-based biologics have expanded to include cancer immunotherapy agents. The following review describes the current state of the art for plant-derived strategies to prevent or reduce cancers. The review discusses avenues taken to prevent infection by oncogenic viruses, solid tumors and lymphomas. Strategies including cancer vaccines, monoclonal antibodies and virus nanoparticles are described, and examples are provided. The review ends with a discussion of the implications of plant-based cancer immunotherapy for developing countries.

show abstract

Plant-Based Vaccines

Cited by 25 publications

References 128 publications

Plants as Factories for Human Pharmaceuticals: Applications and Challenges

Plants as Factories for Human Pharmaceuticals: Applications and Challenges

Repurposing Plant Virus Nanoparticles

Reconceptualizing Cancer Immunotherapy Based on Plant Production Systems

Contact Info

Product

Resources

About